Science and Research

A Phase 3, Open-label Study Evaluating the Long‑term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor Triple Combination Therapy in Cystic Fibrosis Subjects 1 Year of Age and Older

The primary objective of the study is to evaluate the long-term safety and tolerability of
vanzacaftor/tezacaftor/deutivacaftor (VNZ/TEZ/D-IVA)

Study details
Study-ID: NCT05844449, 2022-503081-74-00
Study-ID: NCT05844449, 2022-503081-74-00
DZL Disease Area: CFBE
DZL Disease Area: CFBE
Study Type: Interventional
Study Type: Interventional
DZL Role: DZL recruiting center, DZL on steering board
DZL Role: DZL recruiting center, DZL on steering board
Funding: Externally - industry
Funding: Externally - industry
DZL Participating Sites: BREATH, BIH / Charité - Associated Partner
DZL Participating Sites: BREATH, BIH / Charité - Associated Partner
Start Date: 05.09.2023
Completion Date: 31.10.2030
Status: Enrolling by invitation
Status: Enrolling by invitation
DZL recruiting center, DZL on steering board
Link to Study


close
chevron-down

Unsere Seite verwendet Cookies und ähnliche Technologien. Mit der Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Mehr Informationen dazu finden Sie in unserer Datenschutzerklärung.